Mednax Clinical Leadership Urges Full Vaccination and All Measures to Protect Expecting Mothers and Children During COVID-19 Pandemic

Nation’s Leading Provider of Specialty Maternity and Pediatric Care Advocates for Vulnerable Populations and Those Unable to Become Vaccinated

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--
Mednax®, Inc. (NYSE: MD), its clinical leadership, and that of its affiliated Pediatrix® and Obstetrix® Medical Groups today provided full support of the Centers for Disease Control and Prevention (CDC) and other medical associations’ recommendations that all eligible Americans become vaccinated against COVID-19. This support is consistent with Mednax’s long-standing commitment to the well-being of its affiliated medical practices’ patients nationwide, who consist of women undergoing high-risk pregnancies, critically ill and premature newborns and children in need of specialized and, in many cases, critical care.

This recommendation is also consistent with that of leading clinical associations, including The American College of Obstetricians and Gynecologists, the Society for Maternal-Fetal Medicine, and the American Academy of Pediatrics.

Similar to those for many other historical diseases, COVID-19 vaccinations have been proven as safe and effective. More than 400 million COVID-19 doses have been administered in the U.S. and 6.5 billion doses worldwide, and the overall benefits of the vaccine cannot be disputed. Currently, as many as 90% or more of deaths caused by COVID-19 are occurring in unvaccinated individuals, and infections could be further mitigated by increasing the number of fully vaccinated people.

Clinical leaders across the Mednax organization provided the following statement:

“As clinicians, parents and caring citizens, we are acutely aware of the devastating effect the COVID-19 virus can have on those who have not been vaccinated, and in particular on those who cannot be vaccinated, including newborns and young children. As medical leaders, it is our responsibility to do all we can to protect expecting mothers and children by following every mitigation measure available. This includes proven measures to prevent the virus’ spread including social distancing, masking, hand washing and most importantly, becoming fully vaccinated if eligible. Expecting mothers and children depend on us every day – and they deserve nothing less than to live in an environment where we are all collectively doing what we can to stop the spread of this deadly virus. Maximizing the number of vaccinated individuals not only helps to do just that, but also helps to safeguard the health of those not eligible for the vaccine.”

Signed:

Dr. Mack Hinson, Neonatology, President, Mednax

Dr. Curt Pickert, Pediatric Critical Care Medicine, President, Clinical Services Division

Dr. Renee Higgerson, Pediatric Critical Care Medicine

Dr. Jeff Kane, Pediatric Neurology

Dr. Luissa Kiprono, Maternal-Fetal Medicine

Dr. John Loyd, Neonatology

Dr. Ashish Sureka, Pediatric Cardiology

ABOUT MEDNAX

Mednax, Inc. is a national medical group comprised of the nation’s leading providers of physician services. Physicians and advanced practitioners practicing as part of Mednax’s Pediatrix and Obstetrix Medical Groups are reshaping the delivery of care within their specialties and subspecialties, using evidence-based tools, continuous quality initiatives, clinical research and telehealth programs to enhance patient outcomes and provide high-quality, cost-effective care. The Company was founded in 1979, and today, through its affiliated professional entities, Mednax provides services through a network of more than 2,300 physicians in 39 states and Puerto Rico. Additional information is available at www.mednax.com.

Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not limited to, statements relating to the Company’s objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as “believe,” “hope,” “may,” “anticipate,” “should,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy” and similar expressions, and are based on assumptions and assessments made by the Company’s management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the Company’s most recent Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q, including the sections entitled “Risk Factors”, as well the Company’s current reports on Form 8-K, filed with the Securities and Exchange Commission, and include the impact of the COVID-19 pandemic on the Company and its financial condition and results of operations; the effects of economic conditions on the Company’s business; the effects of the Affordable Care Act and potential changes thereto or a repeal thereof; the Company’s relationships with government-sponsored or funded healthcare programs, including Medicare and Medicaid, and with managed care organizations and commercial health insurance payors; the Company’s ability to comply with the terms of its debt financing arrangements; the impact of the divestiture of the Company’s anesthesiology and radiology medical groups; the impact of management transitions; the timing and contribution of future acquisitions; the effects of share repurchases; and the effects of the Company’s transformation initiatives, including its reorientation on, and growth strategy for, its pediatrics and obstetrics business.

src="https://cts.businesswire.com/ct/CT?id=bwnewssty=20211013005377r1sid=acqr8distro=nxlang=en" style="width:0;height:0" />

View source version on businesswire.com: https://www.businesswire.com/news/home/20211013005377/en/

Charles Lynch
Senior Vice President, Finance and Strategy

954-384-0175 ext. 5692

[email protected]

Source: Mednax, Inc.